Tirzepatide (LY-3298176) — Dual GIP / GLP-1 Receptor Agonist Peptide
Advance metabolic-disease studies with Tirzepatide, the once-weekly peptide that co-activates GIP and GLP-1 receptors. Phase 3 SURMOUNT trials reported up to 22–26 % mean body-weight reduction over 72–88 weeks, underscoring its potency in obesity and T2D research.
-
Purity: > 99 % (HPLC)
-
Molecular Weight: ≈ 4.8 kDa (39 aa)
-
Form & Sizes: Lyophilized powder in 10 mg and 30 mg research-grade vials
-
Solubility: Sterile water or 0.6 % saline (pH ≈ 7)
-
Storage: −20 °C long-term; aliquoted solutions ≤ −80 °C
For laboratory research use only. Not for human or veterinary administration.